Get the Stockscreener App
2.23
0.45%
-0.01
Lantern Pharma Inc stock is traded at $2.23, with a volume of 29,215.
It is down -0.45% in the last 24 hours and down -13.23% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$2.24
Open:
$2.26
24h Volume:
29,215
Relative Volume:
0.56
Market Cap:
$24.94M
Revenue:
-
Net Income/Loss:
$-18.92M
P/E Ratio:
-1.2723
EPS:
-1.7527
Net Cash Flow:
$-16.86M
1W Performance:
-4.29%
1M Performance:
-13.23%
6M Performance:
-51.31%
1Y Performance:
-42.82%
1-Day Range:
$2.20
$2.30
1-Week Range:
$2.03
$2.4035
52-Week Range:
$2.03
$5.7441
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
2.23 | 24.94M | 0 | -18.92M | -16.86M | -1.7527 |
VRTX
Vertex Pharmaceuticals Inc
|
448.62 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
741.69 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
677.50 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
308.05 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.69 | 30.60B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4:30 p.m. ET - BioSpace
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March - PharmiWeb.com
Lantern Pharma Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Lantern Pharma Showcases RADR AI: 70%-80% Faster Drug-to-Clinic Push, 12 FDA Designations - Defense World
Activity Recap: Whats the beta of Lantern Pharma Inc stock2026 Reactions & Community Consensus Trade Signals - baoquankhu1.vn
LTRN: AI-driven innovation is transforming oncology drug development, with key catalysts ahead - TradingView
LTRN: AI-driven drug development yields rapid clinical progress, FDA designations, and new monetization paths - TradingView
Lantern Pharma (LTRN) to Release Earnings on Thursday - Defense World
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET - Quantisnow
Lantern Pharma (LTRN) Stock Forecast and Price Target 2026 $LTRN - MarketBeat
Lake Street Initiates Coverage of Lantern Pharma (LTRN) with Buy Recommendation - MSN
Lantern Pharma (LTRN) Stock Analysis Report | Financials & Insights - Benzinga Japan
Institution Moves: What are Lantern Pharma Incs recent SEC filings showing2025 Institutional Moves & Technical Buy Zone Confirmation - baoquankhu1.vn
What are Lantern Pharma Inc.’s recent SEC filings showingJuly 2025 Review & High Accuracy Trade Alerts - mfd.ru
LTRN Should I Buy - Intellectia AI
Lantern Pharma (LTRN) to Release Quarterly Earnings on Thursday - Defense World
LTRN Technical Analysis & ETF Price Forecast - Intellectia AI
Bull Run: What is Lantern Pharma Incs P E ratio telling usWeekly Market Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
LTRN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Bios group controls 8.58% of Lantern Pharma (LTRN) common stock - Stock Titan
LTRN Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lantern Pharma (LTRN) Advances Oncology AI and Gains Orphan Drug Recognition - Bitget
Aug Gainers: Can Lantern Pharma Inc. stock sustain institutional interestMarket Trend Report & Weekly High Potential Stock Alerts - mfd.ru
Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026 - Business Wire
Enlivex Therapeutics and Lantern Pharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - The Asheville Citizen Times
Growth Report: How much upside does GWRE haveMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Patterns Watch: Is Lantern Pharma Inc stock undervalued right nowJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 - Corpus Christi Caller-Times
Lantern Pharma to Set Up AI Center of Excellence in Bengaluru to Scale RADR Platform - Digital Health News
FDA grants orphan drug designation to Lantern Pharma’s LP-284 for sarcomas - Investing.com Nigeria
Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas - PharmiWeb.com
Lantern Pharma (LTRN) Secures Orphan Drug Designation for LP-284 - GuruFocus
Lantern Pharma Establishes New AI Centre Of Excellence, Agentic Labs Hub In Bengaluru - Voice Of HealthCare
Lantern Pharma Expands Global AI Footprint with Bengaluru Center of Excellence - eHealth Magazine
Critical Comparison: Lantern Pharma (NASDAQ:LTRN) versus Praxis Precision Medicines (NASDAQ:PRAX) - Defense World
FDA Grants Orphan Drug Status to Lantern Pharma's Treatment for Sarcoma (LTRN) - GuruFocus
Lantern Pharma launches AI Center of Excellence in Bengaluru to scale precision drug discovery globally - Indian Pharma Post
Recap Report: Whats the outlook for Lantern Pharma Incs sectorQuarterly Risk Review & Fast Exit and Entry Trade Guides - baoquankhu1.vn
Lantern Pharma establishes AI Centre of Excellence and Advanced Agentic Labs in Bengaluru - BioSpectrum India
History Review: Is Lantern Pharma Inc stock a hidden gemGap Up & Trade Opportunity Analysis Reports - baoquankhu1.vn
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RAD - PharmiWeb.com
Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies - 01net
Lantern Pharma IncEstablishes Ai Center Of Excellence In Bengaluru - TradingView — Track All Markets
Is Lantern Pharma Inc. stock a contrarian buyJuly 2025 Highlights & AI Forecasted Stock Moves - Улправда
Why Lantern Pharma Inc. stock attracts global investorsEarnings Date Calendar & Top Analyst Picks Available for Free - Улправда
Lantern Pharma (NASDAQ:LTRN) Stock Price Up 6.2% – What’s Next? - Defense World
What analysts say about Lantern Pharma Inc stockMarket Capitalization Trends & Superior Capital Growth - earlytimes.in
Lantern Pharma Inc Stock Analysis and ForecastMACD Histogram Signals & Fast Profit Trading Strategies - earlytimes.in
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.80%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):